Entry by Adjacent Industries, Intensifying Competition and Consolidation in the Pharmacy Market
First written in FY2016. 14 of 22 entries say "Restated". Latest entry: FY2026.
Pharmarise Holdings moved to the "Worse" side of this theme in 2020, 2 years before the typical company in this theme (2022).
The whole theme swung hardest in 2026: 21 of 39 companies on the "Worse" side.
39 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Market growth is expected to slow due to the apparent plateauing of the rate of separation between prescribing and dispensing, drug price revisions and efforts to promote the use of generic drugs. In addition, given the current presence of numerous pharmacies, we expect consolidation to progress, including through entry from adjacent industries, leading to oligopolization.」
The Company continues to identify slower market growth, entry from adjacent industries, and consolidation and oligopolization as business-environment risks. - FY2023RestatedAnnual report
「Market growth is expected to slow due to the apparent plateauing of the rate of separation between prescribing and dispensing, drug price revisions and efforts to promote the use of generic drugs. In addition, given the current presence of numerous pharmacies, we expect consolidation to progress, including through entry from adjacent industries, leading to oligopolization.」
The Company continues to identify slower market growth, entry from adjacent industries, and consolidation and oligopolization as business-environment risks. - FY2022RestatedAnnual report
「Given the current presence of numerous pharmacies, we expect consolidation to progress, including through entry from adjacent industries, leading to oligopolization.」
The Company continues to identify slower market growth, entry from adjacent industries, and consolidation and oligopolization as business-environment risks. - FY2022-Q2RestatedAnnual report
「Competition is intensifying due to entry from adjacent industries, while the impact of the April 2018 and April 2020 revisions of medical fees and drug prices, the April 2021 drug price revision and COVID-19 means that the business environment requires further management efforts.」
The Company continues to describe a challenging business environment, including entry from adjacent industries, the past 3 revisions of medical fees and drug prices, and the impact of COVID-19. - FY2022-Q1WorsenedAnnual report
「Competition is intensifying due to entry from adjacent industries, while the impact of the April 2018 and April 2020 revisions of medical fees and drug prices, the April 2021 drug price revision and COVID-19 means that the business environment requires further management efforts.」
In addition to the previously noted intensifying competition, the April 2018 and April 2020 revisions and the impact of COVID-19, the Company newly cites the April 2021 drug price revision. - FY2021RestatedAnnual report
「Given the current presence of numerous pharmacies, we expect consolidation to progress, including through entry from adjacent industries, leading to oligopolization.」
The Company continues to indicate an outlook for slower market growth, entry from adjacent industries, and consolidation and oligopolization. - FY2021-Q3RestatedAnnual report
「Competition is intensifying due to entry from adjacent industries, while the impact of the April 2018 and April 2020 revisions of medical fees and drug prices, together with the impact of COVID-19, means that the business environment requires further management efforts.」
The Company continues to describe a challenging business environment, including entry from adjacent industries, revisions to medical fees and drug prices, and the impact of COVID-19. - FY2021-Q2RestatedAnnual report
「In the dispensing pharmacy industry, competition is intensifying due to entry from adjacent industries. In addition to the impact of the April 2018 and April 2020 revisions of medical fees and drug prices, the impact of COVID-19 means that the business environment requires further management efforts. This is occurring amid demands to expand the use of generic drugs, strengthen initiatives supporting self-medication and respond to the Ministry of Health, Labour and Welfare’s “Pharmacy Vision for Patients,” against the backdrop of social demands including efforts to contain medical costs.」
The Company continues to describe a challenging business environment, including intensifying competition, regulatory changes and the impact of COVID-19. - FY2021-Q1WorsenedAnnual report
「In the dispensing pharmacy industry, competition is intensifying due to entry from adjacent industries. In addition to the impact of the April 2018 and April 2020 revisions of medical fees and drug prices, the impact of COVID-19 means that the business environment requires further management efforts. This is occurring amid demands to expand the use of generic drugs, strengthen initiatives supporting self-medication and respond to the Ministry of Health, Labour and Welfare’s “Pharmacy Vision for Patients,” against the backdrop of social demands including efforts to contain medical costs.」
In addition to the previously noted intensifying competition and the impact of revisions to medical fees and drug prices, the Company describes the impact of COVID-19 as making the business environment one that requires further management efforts. - FY2020WorsenedAnnual report
「Due to drug price revisions, the further adoption of generic drugs and the expected continued containment of dispensing fees, prescription value per item is expected to decline. Over the medium to long term, growth at the levels seen in the past will become less attainable, and we expect the gradual decline in profit margins cannot be avoided without implementing bold management improvement measures. At the same time, given the current presence of numerous pharmacies, we expect consolidation to progress, including through entry from adjacent industries, leading to oligopolization.」
The Company continues to explicitly indicate the risk of lower profit margins due to slower market growth and declining prescription value per item, as well as an outlook for consolidation and oligopolization, including through entry from adjacent industries. - FY2020-Q3WorsenedAnnual report
「In the dispensing pharmacy industry, competition is intensifying due to entry from adjacent industries, while the impact of the April 2018 revision of medical fees and drug prices, together with the implementation of revisions to medical fees and drug prices in April 2020, means that the business environment continues to require greater management efforts. This is occurring amid demands to expand the use of generic drugs, strengthen initiatives supporting self-medication and respond to the Ministry of Health, Labour and Welfare’s “Pharmacy Vision for Patients,” against the backdrop of social demands including efforts to contain medical costs.」
In addition to the previously noted intensifying competition and impact of the April 2018 revision, the Company refers to the April 2020 revision of medical fees and drug prices and describes the business environment as one that continues to require greater management efforts. - FY2020-Q2RestatedAnnual report
「In the dispensing pharmacy industry, competition is intensifying due to entry from adjacent industries, while the impact of the April 2018 revision of medical fees and drug prices also requires greater management efforts. These pressures arise amid demands to expand the use of generic drugs, strengthen initiatives supporting self-medication and respond to the Ministry of Health, Labour and Welfare’s “Pharmacy Vision for Patients,” against the backdrop of social demands including efforts to contain medical costs.」
The Company continues to describe intensifying competition, responding to regulatory changes and the impact of the April 2018 revision of medical fees and drug prices as aspects of a challenging business environment. - FY2020-Q1RestatedAnnual report
「In the dispensing pharmacy industry, competition is intensifying due to entry from adjacent industries, while the impact of the April 2018 revision of medical fees and drug prices also requires greater management efforts. These pressures arise amid demands to expand the use of generic drugs, strengthen initiatives supporting self-medication and respond to the Ministry of Health, Labour and Welfare’s “Pharmacy Vision for Patients,” against the backdrop of social demands including efforts to contain medical costs.」
The Company continues to describe intensifying competition, responding to regulatory changes and the impact of the April 2018 revision as aspects of a challenging business environment. - FY2019-Q3RestatedAnnual report
「In the dispensing pharmacy industry, competition is intensifying due to entry from adjacent industries, while the impact of the April 2018 revision of medical fees and drug prices has become extremely severe. The business environment requires greater management efforts amid demands to expand the use of generic drugs, strengthen initiatives supporting self-medication and respond to the Ministry of Health, Labour and Welfare’s “Pharmacy Vision for Patients,” against the backdrop of social demands including efforts to contain medical costs.」
The Company continues to describe intensifying competition, responding to regulatory changes and the severe impact of the April 2018 revision as aspects of the business environment in the dispensing pharmacy industry. - FY2019-Q1WorsenedAnnual report
「In the dispensing pharmacy industry, competition is intensifying due to entry from adjacent industries, while the impact of the April 2018 revision of medical fees and drug prices has become extremely severe. The business environment requires greater management efforts amid demands to expand the use of generic drugs, strengthen initiatives supporting self-medication and respond to the Ministry of Health, Labour and Welfare’s “Pharmacy Vision for Patients,” against the backdrop of social demands including efforts to contain medical costs.」
Regarding the impact of revisions to medical fees and drug prices, the wording has changed from an expectation of a severe impact to a statement that the impact has “become extremely severe.” - FY2018WorsenedAnnual report
「The market’s growth rate is expected to slow due to drug price revisions and stronger efforts to promote the use of generic drugs. We expect the market to remain broadly flat over the medium to long term. Given the current presence of numerous pharmacies, we believe consolidation will progress, including through entry from adjacent industries, leading to oligopolization by large-capital operators.」
The Company explicitly indicates an outlook for slower or flat market growth, consolidation including entry from adjacent industries, and oligopolization by large-capital operators. - FY2018-Q3RestatedAnnual report
「In the dispensing pharmacy industry, the business environment is becoming one that requires greater management efforts. Amid demands to expand the use of generic drugs, strengthen initiatives supporting self-medication and respond to the Ministry of Health, Labour and Welfare’s “Pharmacy Vision for Patients,” against the backdrop of social demands including efforts to contain medical costs, competition is intensifying due to entry from adjacent industries, while the impact of the April 2018 revision of medical fees and drug prices is also expected to be severe.」
The Company continues to identify intensifying competition due to entry from adjacent industries and the expected severe impact of revisions to medical fees and drug prices as business-environment challenges. - FY2018-Q2WorsenedAnnual report
「In the dispensing pharmacy industry, the business environment is becoming one that requires greater management efforts. Amid demands to expand the use of generic drugs, strengthen initiatives supporting self-medication and respond to the Ministry of Health, Labour and Welfare’s “Pharmacy Vision for Patients,” against the backdrop of social demands including efforts to contain medical costs, competition is intensifying due to entry from adjacent industries. In addition, the impact of the April 2018 revision of medical fees and drug prices is expected to be severe.」
In addition to intensifying competition due to entry from adjacent industries, the Company expects the impact of the April 2018 revision of medical fees and drug prices to be severe. - FY2017-Q3RestatedAnnual report
「In the dispensing pharmacy industry, the business environment is becoming one that requires greater management efforts. Against the backdrop of social demands, including efforts to contain medical costs, these include expanding the use of generic drugs, strengthening initiatives supporting self-medication, and responding to the Ministry of Health, Labour and Welfare’s “Pharmacy Vision for Patients,” while competition is intensifying due to entry from adjacent industries and other factors.」
The Company continues to describe intensifying competition, responding to generic drugs and self-medication, and responding to the Pharmacy Vision for Patients as aspects of a challenging business environment. - FY2017-Q2RestatedAnnual report
「In the dispensing pharmacy industry, the business environment is becoming one that requires greater management efforts. Against the backdrop of social demands, including efforts to contain medical costs, these include expanding the use of generic drugs, strengthening initiatives supporting self-medication, and responding to the Ministry of Health, Labour and Welfare’s “Pharmacy Vision for Patients,” while competition is intensifying due to entry from adjacent industries and other factors.」
In addition to intensifying competition, the Company continues to describe responding to generic drugs and self-medication against the backdrop of efforts to contain medical costs, as well as responding to the Pharmacy Vision for Patients, as aspects of a challenging business environment. - FY2017-Q1RestatedAnnual report
「In the dispensing pharmacy industry, the business environment is becoming one that requires greater management efforts, as competition intensifies due to entry from adjacent industries and other factors, while the Company must adapt to the Ministry of Health, Labour and Welfare’s “Pharmacy Vision for Patients,” which is based on strengthening the functions of “primary pharmacists and pharmacies,” and address the increasingly serious shortage of pharmacists.」
The Company continues to identify intensifying competition, adaptation to primary pharmacy functions and the shortage of pharmacists as business-environment challenges. - FY2016First statedAnnual report
「In addition to intensifying competition due to entry by adjacent industries and other factors, the business environment requires greater management efforts to adapt to the Ministry of Health, Labour and Welfare’s <r0>Vision for Pharmacies for Patients</r0>, which focuses on strengthening the functions of family pharmacists and pharmacies, and to address the increasingly serious shortage of pharmacists.」
In addition to intensifying competition, the company identifies the potential for industry restructuring and consolidation by large-capital operators as a risk.